trial · primary record
Efgartigimod PH20 SC
Graves' Disease
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 230 |
| Primary completion | 2030-05 |
| Primary endpoint | Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part A |
| Registry ID | NCT07570316 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:56.335Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07570316
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- efgartigimod PH20 SC · compound